Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | TYK2 | P29597 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | JAK1 | P23458 | 1/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.49 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | TDP2 | O95551 | 1/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GALK1 | P51570 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3780962 | 0.88 | DOT1L (0.50) | DOT1LALDH1A1TYK2HPGDJAK2 | |
| SCHEMBL7457606 | 0.86 | JAK1 (0.58) | DOT1LALDH1A1TYK2HPGDJAK2 | |
| SCHEMBL14968580 | 0.86 | GAA (0.63) | TYK2HPGDJAK2CYP3A4JAK1 | |
| SCHEMBL15628897 | 0.86 | TYK2 (0.61) | DOT1LALDH1A1TYK2HPGDJAK2 | |
| SCHEMBL7457599 | 0.83 | KDM4E (0.47) | DOT1LALDH1A1HPGDRAB9AGAA | |
| SCHEMBL20275217 | 0.83 | ALDH1A1 (0.50) | DOT1LALDH1A1TYK2HPGDJAK2 | |
| SCHEMBL6428937 | 0.83 | DOT1L (0.50) | DOT1LALDH1A1TYK2HPGDJAK2 | |
| SCHEMBL8857056 | 0.83 | GAA (0.53) | DOT1LALDH1A1TYK2HPGDJAK2 | |
| SCHEMBL29971273 | 0.82 | CYP2A6 (0.47) | DOT1LALDH1A1HPGDRAB9AKDM4E | |
| SCHEMBL20275216 | 0.82 | ALDH1A1 (0.46) | DOT1LALDH1A1TYK2HPGDJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377768-B2 | Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | LYCERA CORPORATION (US) | 2019-08-13 | — | — | US | disclosed |
| WO-2019062802-A1 | ISOXAZOLINE DERIVATIVES AND THEIR USES IN AGRICULTURE RELATED APPLICATION | DONGGUAN HEC TECH R & D CO., LTD. (CN) | 2019-04-04 | — | — | WO | disclosed |
| US-10208061-B2 | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-02-19 | — | — | US | disclosed |
| EP-2806898-B1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4 | HOFFMANN LA ROCHE (CH) | 2018-07-18 | — | — | EP | disclosed |
| US-20180179224-A1 | Tetrahydro[1,8]naphthyridine Sulfonamide And Related Compounds for Use as Agonists of RORy and the Treatment of Disease | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-06-28 | — | — | US | disclosed |
| EP-2846804-B1 | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170313722-A1 | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2017-11-02 | — | — | US | disclosed |
| EP-2846794-B1 | BICYCLIC SULFONE COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9802958-B2 | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease | LYCERA CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-9657033-B2 | Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease | LYCERA CORPORATION (US) | 2017-05-23 | — | — | US | disclosed |
| WO-2013110681-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-01 | — | — | WO | disclosed |
| US-20130079383-A1 | Lipid Compounds Targeting VLA-4 | ARROWHEAD RESEARCH CORPORATION (US) | 2013-03-28 | — | — | US | disclosed |
| US-20120220552-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE BAHAMAS LIMITED (BS) | 2012-08-30 | — | — | US | disclosed |
| US-20120220552-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE BAHAMAS LIMITED (BS) | 2012-08-30 | — | — | US | disclosed |
| US-8247377-B2 | Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions | GLAXO GROUP LIMITED (GB) | 2012-08-21 | — | — | US | disclosed |
| WO-2011023795-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2011-03-03 | — | — | WO | disclosed |
| US-20100234441-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| US-20090131657-A1 | PROCESS FOR ALKENYLATING CARBOXAMIDES | BASF SE (DE) | 2009-05-21 | — | — | US | disclosed |
| US-7361679-B2 | 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2008-04-22 | — | — | US | disclosed |
| US-7361679-B2 | 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2008-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234441-A1 | NOVEL COMPOUNDS | LTB4R2, TSLP, LTB4R | DOT1L 4470/4885ALDH1A1 615/4885TYK2 1543/4885 |
| US-10377768-B2 | Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | RORC, RORB, RORA | DOT1L 3218/4885ALDH1A1 1640/4885TYK2 350/4885 |
| US-20120220552-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | S1PR3, S1PR1, S1PR2 | DOT1L 1113/4885ALDH1A1 3626/4885TYK2 1480/4885 |
| US-20170313722-A1 | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORC, RORB, RORA | DOT1L 3218/4885ALDH1A1 1640/4885TYK2 350/4885 |
| US-20130079383-A1 | Lipid Compounds Targeting VLA-4 | LPAR4, ASGR1, VCAM1 | DOT1L 2302/4885ALDH1A1 997/4885TYK2 3710/4885 |
| US-20180179224-A1 | Tetrahydro[1,8]naphthyridine Sulfonamide And Related Compounds for Use as Agonists of RORy and the Treatment of Disease | RORA, RORC, RORB | DOT1L 2795/4885ALDH1A1 224/4885TYK2 566/4885 |
| US-10208061-B2 | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORC, RORA, RORB | DOT1L 3160/4885ALDH1A1 322/4885TYK2 521/4885 |
| US-20090131657-A1 | PROCESS FOR ALKENYLATING CARBOXAMIDES | PRMT5, CYC1, CBR3 | DOT1L 136/4885ALDH1A1 1506/4885TYK2 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.